Endocrine Abstracts (2012) 28 AP1.2

Nanoparticles for molecular imaging of angiogenesis and targeted antiangiogenic therapy

Gregory Lanza


Department of Medicine, Division of Cardiology, Washington University Medical School, St Louis, MT.


Over the last decade, high-resolution molecular imaging with nanoparticle has provided an unprecedented opportunity to noninvasively assess microanatomical neovascular processes associated with atherosclerosis, cancer, or arthritis as a “snap shot” or longitudinally with time. The capability to interogate biochemical markers in vivo in 3D over relatively large volumes of tissues facilitates a unique perspective of physiological and disease processes that cannot be easily appreciated with traditional microscopic inspection of 5–10 µ slices. Moreover, the use of nanoparticles affords a further opportunity to deliver highly potent drugs to great effect with lower total body exposures. For almost a century, Erlich’s concept of a “magic bullet” has eluded medicine, but today the first generation products addressing this vision are in clinical trials. These image-driven technologies offer both clinical and research benefits that were not conceivable only a decade earlier. We will review the current status of angiogenesis imaging and targeted therapy using theranostic nanoplatforms and complementary prodrugs developed at CTRAIN.

Declaration of interest: There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding: No specific grant from any funding agency in the public, commercial or not-for-profit sector.

Article tools

My recent searches

No recent searches.